Literature DB >> 18558948

In vitro susceptibility of Cryptococcus gattii clinical isolates.

A Gomez-Lopez1, O Zaragoza, M Dos Anjos Martins, M C Melhem, J L Rodriguez-Tudela, M Cuenca-Estrella.   

Abstract

The data available in the literature concerning Cryptococcus gattii in vitro antifungal susceptibility are contradictory. We have analyzed the activity of eight antifungal agents against 23 C. gattii clinical isolates and compared the susceptibility profiles with those of C. neoformans. MIC analysis (mg/L) revealed that C. gattii isolates were more susceptible to amphotericin B and flucytosine than were C. neoformans isolates. Fluconazole and other azole compounds showed high MIC values for C. gattii. Posaconazole displayed good activity. Further studies are required to ascertain the predictive value of the in vitro data presented here.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18558948     DOI： 10.1111/j.1469-0691.2008.02021.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN： 1198-743X            Impact factor:   8.067


  19 in total

1.  Comparison of the Vitek 2 antifungal susceptibility system with the clinical and laboratory standards institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) Broth Microdilution Reference Methods and with the Sensititre YeastOne and Etest techniques for in vitro detection of antifungal resistance in yeast isolates.

Authors:  Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Ana Alastruey-Izquierdo; Leticia Bernal-Martinez; Isabel Cuesta; Maria J Buitrago; Juan L Rodriguez-Tudela
Journal:  J Clin Microbiol       Date:  2010-03-10       Impact factor: 5.948

2.  Identification and properties of plasma membrane azole efflux pumps from the pathogenic fungi Cryptococcus gattii and Cryptococcus neoformans.

Authors:  Luiz R Basso; Charles E Gast; Igor Bruzual; Brian Wong
Journal:  J Antimicrob Chemother       Date:  2015-01-27       Impact factor: 5.790

3.  Antifungal therapy in a murine model of disseminated infection by Cryptococcus gattii.

Authors:  Enrique Calvo; F Javier Pastor; M Mar Rodríguez; Isabel Pujol; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2010-07-12       Impact factor: 5.191

4.  Heteroresistance of Cryptococcus gattii to fluconazole.

Authors:  A Varma; K J Kwon-Chung
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

5.  Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine.

Authors:  A Espinel-Ingroff; A Chowdhary; M Cuenca-Estrella; A Fothergill; J Fuller; F Hagen; N Govender; J Guarro; E Johnson; C Lass-Flörl; S R Lockhart; M A Martins; J F Meis; M S C Melhem; L Ostrosky-Zeichner; T Pelaez; M A Pfaller; W A Schell; L Trilles; S Kidd; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

6.  Molecular typing of clinical isolates of Cryptococcus neoformans/Cryptococcus gattii species complex from Northeast Mexico.

Authors:  Gloria M González; Néstor Casillas-Vega; Elvira Garza-González; Romel Hernández-Bello; Gildardo Rivera; Jesús Ancer Rodríguez; Virgilio Bocanegra-Garcia
Journal:  Folia Microbiol (Praha)       Date:  2015-06-25       Impact factor: 2.099

Review 7.  Cryptococcus gattii infections.

Authors:  Sharon C-A Chen; Wieland Meyer; Tania C Sorrell
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

8.  In vitro susceptibility of the yeast pathogen cryptococcus to fluconazole and other azoles varies with molecular genotype.

Authors:  Hin Siong Chong; Rebecca Dagg; Richard Malik; Sharon Chen; Dee Carter
Journal:  J Clin Microbiol       Date:  2010-09-15       Impact factor: 5.948

9.  Roles of Three Cryptococcus neoformans and Cryptococcus gattii Efflux Pump-Coding Genes in Response to Drug Treatment.

Authors:  Miwha Chang; Edward Sionov; Ami Khanal Lamichhane; Kyung J Kwon-Chung; Yun C Chang
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

10.  Cryptococcus gattii: An Emerging Cause of Fungal Disease in North America.

Authors:  Ashwin Dixit; Scott F Carroll; Salman T Qureshi
Journal:  Interdiscip Perspect Infect Dis       Date:  2009-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.